One of Australia's most popular pain killers has been left with a splitting headache, as the national consumer watchdog gets ready to take it to court. Reckitt Benckiser, the company behind Nurofen in Australia, will square off against the Australian Competition and Consumer Commission (ACCC) in federal court this month over claims that it has mislead customers. The ACCC will dispute claims made by the company that the Nurofen Specific Pain Range is specially designed to target different types of pain. The consumer watchdog claims that all products contain identical ingredients. Scroll down for video. Australia's consumer watchdog is taking Nurofen to court over its advertising claiming its products target  specific types of pain. The products in question are: Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension Headache. ACCC Chairman Rod Sims said cracking down on false advertising surrounding medical products was a targetted priority for the watchdog. 'The ACCC takes false or misleading claims about the efficacy of health and medical products very seriously,' Mr Sims said. 'In this case, we allege that consumers have been misled into purchasing Nurofen Specific Pain Products under the belief that each product is specifically designed for and effective in treating a particular type of pain, when this is not the case.' 'The ACCC takes false or misleading claims about the efficacy of health and medical products very seriously,' chairman Rod Sims said. It also flagged the 'significantly' higher cost of Nurofen compared to other products as a concern, with the range in question costing up to twice as much as a standard pain killer sold by Nurofen or another comparable brand. A Nurofen spokeswoman denied the allegations in a statement, and said pain-specific products made life easier for customers. 'Nurofen is committed to the quality use of medicines and promoting and protecting the health of Australians,' the statement read. 'Nurofen works closely with all regulatory bodies to ensure high standards compliance to guidelines. 'Nurofen will continue to work with regulators to ensure its packaging continues to be fully aligned with all guidelines and requirements and still offer consumers with clear pain relief options for their pain type.' The ACCC is seeking declarations, injunctions, an order for the publication of corrective notices, penalties and costs. The matter is listed for a case management conference  in the Federal Court of Australia in Sydney on March 31.
Here is a summary of the highlights for this article:
Australian Competition and Consumer Commission takes it to federal court.
Alleges Nurofen claims 'misleading customers', all tablets exactly the same.
ACCC says all pills have the same key ingredient, ibuprofen lysine 342mg.
Calls for 'truth in advertising' across medical industry to become priority.
Case to go before Federal Court of Australia in Sydney on March 31.
En av Australiens mest populära smärtstillande har lämnats med en splittrande huvudvärk, som den nationella konsument vakthunden gör sig redo att ta det till domstol. Reckitt Benckiser, företaget bakom Nurofen i Australien, kommer att kvitta mot Australian Competition and Consumer Commission (ACCC) i federal domstol denna månad över hävdar att det har vilselett kunder. Den MEDBROTTSLING kommer att bestrida påståenden som gjorts av företaget att Nurofen Specific Pain Range är speciellt utformad för att rikta olika typer av smärta. Konsumentvakten hävdar att alla produkter innehåller identiska ingredienser. Scrolla ner för video. Australiens konsument vakthund tar Nurofen till domstol över sin reklam hävdar sina produkter rikta specifika typer av smärta. Produkterna i fråga är: Nurofen ryggsmärta, Nurofen period smärta, Nurofen migrän smärta och Nurofen spänning huvudvärk. CCCC ordförande Rod Sims sade att slå ner på falsk reklam kring medicinska produkter var en måltavla prioritet för vakthunden. "Medborgarna i MEDBROTTSLINGEN tar falska eller vilseledande påståenden om hälso- och sjukvårdsprodukters effektivitet på stort allvar", sade Sims. "I det här fallet hävdar vi att konsumenterna har vilseletts att köpa Nurofen Specifika Pain Products under tron att varje produkt är särskilt utformad för och effektiv vid behandling av en viss typ av smärta, när så inte är fallet." " MEDBROTTSLINGEN tar falska eller vilseledande påståenden om hälso- och sjukvårdsprodukters effektivitet på stort allvar", sade ordförande Rod Sims. Den markerade också den "betydande" högre kostnaden för Nurofen jämfört med andra produkter som ett problem, med det aktuella sortimentet kostar upp till dubbelt så mycket som en standard smärtstillande som säljs av Nurofen eller ett annat jämförbart varumärke. En Nurofen taleskvinna förnekade anklagelserna i ett uttalande, och sade smärtspecifika produkter gjorde livet lättare för kunderna. ”Nurofen har åtagit sig att använda läkemedel av hög kvalitet och att främja och skydda australiensarnas hälsa”, löd uttalandet. "Nurofen har ett nära samarbete med alla regleringsorgan för att säkerställa att riktlinjerna följs av höga standarder. ”Nurofen kommer att fortsätta att arbeta med tillsynsmyndigheter för att säkerställa att dess förpackningar fortsätter att vara helt i linje med alla riktlinjer och krav och fortfarande erbjuda konsumenterna tydliga smärtlindringsalternativ för sin smärttyp.” MEDBROTTSLINGSPROCESSEN begär deklarationer, förelägganden, en order om offentliggörande av korrigerande meddelanden, påföljder och kostnader. Ärendet är listat för en ärendehanteringskonferens i den federala domstolen i Australien i Sydney den 31 mars. Här är en sammanfattning av höjdpunkterna för denna artikel:
One of Australia's most popular painkillers has been left with a divisive headache, as the national consumer watchdog is getting ready to take it to court. Reckitt Benckiser, the company behind Nurofen in Australia, will set off against the Australian Competition and Consumer Commission (ACCC) in federal court this month over claims it has misled customers. The ACCC will contest claims made by the company that the Nurofen Specific Pain Range is specially designed to target various types of pain. The consumer guard claims that all products contain identical ingredients. Scroll down for video. Australia's consumer watchdog takes Nurofen to court over its advertising claims its products target specific types of pain. The products in question are: Nurofen back pain, Nurofen period pain, Nurofen migraine pain and Nurofen tension headache. CCCC chairman Rod Sims said striking down on fake advertising around medical products was a target priority for the watchdog. "Citizens in the ACCC take false or misleading claims about the effectiveness of healthcare products very seriously," Sims said. "In this case, we claim that consumers have been misled into buying Nurofen Specific Pain Products under the belief that each product is specially designed for and effective in treating a particular type of pain, when not." "THE ACCC takes false or misleading claims about the effectiveness of healthcare products very seriously," said Chairman Rod Sims. It also marked the "significant" higher cost of Nurofen compared to other products as a problem, with the current range costing up to twice as much as a standard painkiller sold by Nurofen or another comparable brand. A Nurofen spokeswoman denied the allegations in a statement, saying pain-specific products made life easier for customers. ‘Nurofen is committed to the use of high quality medicines and to the promotion and protection of Australian health’, the statement read. "Nurofen works closely with all regulatory bodies to ensure that the guidelines are followed by high standards. “Nurofen will continue to work with regulators to ensure that its packaging continues to be fully in line with all guidelines and requirements and still offer consumers clear pain relief options for their type of pain.” THE ACCC PROCESS requests declarations, injunctions, an order for publication of corrective notices, penalties and costs. The case is listed for a case-handling conference in the Federal Court of Australia in Sydney on 31 March. Here is a summary of the highlights of this article:
Australian Competition and Consumer Commission tar det till federal domstol. Enligt Nurofen hävdar "missledande kunder", alla surfplattor exakt likadana. MEDBROTTSLING säger att alla piller har samma nyckelingrediens, ibuprofen lysin 342mg. Parlamentet kräver att ”sanning i reklam” i hela den medicinska industrin prioriteras. Mål att gå till Federal Court of Australia i Sydney den 31 mars.
The Australian Competition and Consumer Commission takes it to federal court. According to Nurofen, "misleading customers", all tablets claim exactly the same. ACCC says all pills have the same key ingredient, ibuprofen lysine 342mg. calls for priority to be given to ‘truth in advertising’ throughout the medical industry; Case to go to the Federal Court of Australia in Sydney on 31 March.